Brought to you by 
GSK, Allergan cross license Botox, Imitrex, and Amerge
02 Nov 2005
Executive Summary
GlaxoSmithKline PLC and Allergan have entered into a cross-licensing agreement that gives GSK development and marketing rights in Japan and China to Allergan's neuromodulator Botox (botulinum toxin type A), and Allergan US co-promotion rights for five years to GSK's migraine drugs Amerge (naratriptan) tablets and Imitrex Statdose System (sumatriptan succinate) for injection.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Site Specific
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK, Allergan cross license Botox, Imitrex, and Amerge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice